What is he best known for?
The fields of study Myron S. Czuczman is best known for:
- Cancer
- Chemotherapy
- Antibody
In his articles, Myron S. Czuczman combines various disciplines, including Lymphoma and Diffuse large B-cell lymphoma.
Myron S. Czuczman applies his multidisciplinary studies on Diffuse large B-cell lymphoma and Lymphoma in his research.
His study brings together the fields of Pharmacokinetics and Internal medicine.
His research on Pharmacokinetics often connects related areas such as Internal medicine.
Rituximab and International Prognostic Index are two areas of study in which Myron S. Czuczman engages in interdisciplinary research.
He performs multidisciplinary study in the fields of International Prognostic Index and Rituximab via his papers.
Myron S. Czuczman connects Chemotherapy with Phases of clinical research in his research.
His Phases of clinical research study frequently draws connections to other fields, such as Surgery.
His Surgery study frequently draws parallels with other fields, such as Neutropenia.
His most cited work include:
- Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma (1069 citations)
- Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy (822 citations)
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity (653 citations)
What are the main themes of his work throughout his whole career to date
As part of his Cyclophosphamide, Neutropenia and Phases of clinical research and Chemotherapy studies, Myron S. Czuczman is studying Chemotherapy.
Myron S. Czuczman incorporates Cyclophosphamide and Rituximab in his studies.
Rituximab and Follicular lymphoma are two areas of study in which Myron S. Czuczman engages in interdisciplinary work.
Borrowing concepts from Antibody, he weaves in ideas under Follicular lymphoma.
He conducted interdisciplinary study in his works that combined Antibody and Radioimmunotherapy.
He regularly ties together related areas like Adverse effect in his Internal medicine studies.
While working on this project, he studies both Lymphoma and Diffuse large B-cell lymphoma.
Myron S. Czuczman brings together Diffuse large B-cell lymphoma and Lymphoma to produce work in his papers.
In his research, he performs multidisciplinary study on Oncology and Gastroenterology.
Myron S. Czuczman most often published in these fields:
- Internal medicine (83.45%)
- Lymphoma (83.45%)
- Rituximab (61.15%)
What were the highlights of his more recent work (between 2015-2021)?
- Lymphoma (90.00%)
- Rituximab (90.00%)
- Internal medicine (80.00%)
In recent works Myron S. Czuczman was focusing on the following fields of study:
In his research, Myron S. Czuczman undertakes multidisciplinary study on Lymphoma and Follicular lymphoma.
His work blends Follicular lymphoma and CD20 studies together.
He merges many fields, such as CD20 and Rituximab, in his writings.
He combines Rituximab and International Prognostic Index in his research.
Myron S. Czuczman combines International Prognostic Index and Diffuse large B-cell lymphoma in his studies.
He merges many fields, such as Diffuse large B-cell lymphoma and Multiple myeloma, in his writings.
He merges many fields, such as Multiple myeloma and Lymphoma, in his writings.
His research on Internal medicine frequently links to adjacent areas such as Confidence interval.
He conducts interdisciplinary study in the fields of Confidence interval and Hazard ratio through his research.
Between 2015 and 2021, his most popular works were:
- A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (121 citations)
- Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents (57 citations)
- Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development (38 citations)
In his most recent research, the most cited works focused on:
- Chemotherapy
- Clinical trial
- Multiple myeloma
His Internal medicine study frequently involves adjacent topics like Neutropenia.
Myron S. Czuczman combines Neutropenia and Febrile neutropenia in his research.
His research on Febrile neutropenia often connects related areas such as Surgery.
His research brings together the fields of Data monitoring committee and Surgery.
Myron S. Czuczman integrates Data monitoring committee with Clinical trial in his study.
He applies his multidisciplinary studies on Clinical trial and Randomized controlled trial in his research.
His Randomized controlled trial study frequently draws connections to other fields, such as Internal medicine.
Myron S. Czuczman integrates Chemotherapy with Cancer research in his study.
His study deals with a combination of Cancer research and Chemotherapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
